As it is known that IRE1α indirectly activates various proteins, including BCL2, it seems possible that inhibitors of BCL2 family members may exhibit synergism with IRE1α inhibitors in blood cancer treatment. Here, ERN1 is linked to hematopoietic and lymphoid system neoplasm.